Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

	☐	Rule 13d-1(b)
	☒	Rule 13d-1(c)
	☐	Rule 13d-1(d)

(1)	See Item 4 below.
(2)	The percentage ownership interest is determined based on 48,258,111 shares of Common Stock outstanding as of November 1, 2024, as reported on the Issuer’s Form 10-Q, filed on November 7, 2024.

Item 1 (a).

Name of Issuer:

Item 1(b).

Address of Issuer’s Principal Executive Offices:

Item 2(a).

Name of Persons Filing:

Item 2(b).

Address of Principal Business Office or, if None, Residence:

	BMS	Celgene
	Route 206 & Province Line Road	Route 206 & Province Line Road
	Princeton, New Jersey 08543	Princeton, New Jersey 08543

Item 2(c).

Citizenship:

Item 2(d).

Title of Class of Securities:

Item 2(e).

CUSIP Number:

Item 3.

If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
	(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
	(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
	(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
	(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
	(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
	(j)	☐	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
	(k)	☐	Group, in accordance with § 240.13d–1(b)(1)(ii)(K).

Item 4.

Ownership.

	(a)	Amount beneficially owned:
		2,133,142 shares of Common Stock of the Issuer*

	(b)	Percent of class: 4.4%**
	(c)	Number of shares as to which such person has:
		(i)	Sole power to vote or to direct the vote:
			0

	(ii)	Shared power to vote or to direct the vote:
		2,133,142 shares of Common Stock of the Issuer*

	(iii)	Sole power to dispose or to direct the disposition of:
		0

	(iv)	Shared power to dispose or to direct the disposition of:
		2,133,142 shares of Common Stock of the Issuer*

Item 5.

Ownership of Five Percent or Less of a Class.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Item 8.

Identification and Classification of Members of the Group.

Item 9.

Notice of Dissolution of Group.

Item 10.

Certifications.

Exhibit Description
99.1	Joint Filing Agreement, dated April 5, 2021, between BMS and Celgene.

Date: November 13, 2024
	BRISTOL-MYERS SQUIBB COMPANY /s/ Amy Fallone
		Name:	Amy Fallone
		Title:	Corporate Secretary
	CELGENE CORPORATION /s/ Amy Fallone
		Name:	Amy Fallone
		Title:	Vice President and Secretary